Oncolytics Biotech has announced that its drug, pelareorep, has been selected for inclusion in Precision PromiseSM, a Phase 3 clinical trial designed to evaluate the drug in combination with checkpoint inhibitors and chemotherapeutic agents gemcitabine and nab-paclitaxel. The trial is expected to support approval of the studied combination as a treatment for first-line metastatic pancreatic ductal adenocarcinoma (PDAC). Pelareorep's inclusion in Precision Promise is supported by prior clinical data in pancreatic cancer that suggests it synergizes with checkpoint inhibition and chemotherapy.
Oncolytics expects to finalize agreements within 90 days and open the investigational treatment of pelareorep, checkpoint inhibitor, gemcitabine, and nab-paclitaxel in early 2024. If successful, the new clinical study is expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial.
Keywords: Oncolytics Biotech, pelareorep, Precision PromiseSM, pancreatic cancer therapies
Oncoly